Related Experiment Videos
Cardiogenic hepatorenal syndrome
J E Naschitz1, D Yeshurun, J Shahar
1Department of Internal Medicine, A, Bnai Zion Medical Center, Haifa, Israel.
Angiology
|November 1, 1990
Summary
This study describes cardiogenic hepatorenal syndrome, a heart failure complication. Low-dose dopamine showed potential in treating this severe condition, improving outcomes in some patients.
Area of Science:
- Cardiology
- Nephrology
- Hepatology
Background:
- Congestive heart failure can lead to serious complications.
- Cardiogenic pulmonary edema is a critical event in heart failure.
- Hepatorenal syndrome is a recognized complication of liver disease and circulatory dysfunction.
Purpose of the Study:
- To describe a specific variant of hepatorenal syndrome in patients with chronic congestive heart failure.
- To characterize the clinical and laboratory features of this condition.
- To evaluate the efficacy of dopamine in managing cardiogenic hepatorenal syndrome.
Main Methods:
- Observational study over eleven years.
- Clinical assessment of 13 patients.
- Analysis of laboratory data including liver enzymes, coagulation profile, renal function tests, and electrolytes.
- Evaluation of treatment outcomes with conventional medication and the addition of dopamine.
Main Results:
- Identified 13 cases of a hepatorenal syndrome variant in heart failure patients without hypotension.
- Observed significant hepatic injury (elevated transaminases) and renal impairment (elevated creatinine, BUN, potassium; decreased urinary sodium).
- Conventional treatment resulted in death in 4 cases; dopamine administration led to recovery in 5 of 9 patients.
Conclusions:
- Cardiogenic hepatorenal syndrome is a severe but potentially reversible complication of heart failure.
- Low-dose dopamine may offer a beneficial therapeutic effect in managing this condition.
- Further research is needed to validate the efficacy of dopamine in treating cardiogenic hepatorenal syndrome.